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Abstract
Objectives: To assess the range of hepatobiliary enhance-
ment patterns of focal nodular hyperplasia (FNH) after
gadoxetic-acid injection, and to correlate these patterns
to specific histological features.
Materials and methods: FNH lesions, imaged with
Gadoxetic-acid-enhanced MRI, with either typical imag-
ing findings on T1, T2 and dynamic-enhanced sequences
or histologically proven, were evaluated for hepatobiliary
enhancement patterns and categorized as homogeneously
hyperintense, inhomogeneously hyperintense, iso-intense,
or hypo-intense-with-ring. Available histological speci-
mens of FNHs (surgical resection or histological biopsy),
were re-evaluated to correlate histological features with
observed enhancement patterns.
Results: 26 FNHs in 20 patients were included; histology
was available in six lesions (four resections, two biopsies).
The following distribution of enhancement patterns was
observed: 10/26 homogeneously hyperintense, 4/26 inho-
mogeneously hyperintense, 5/26 iso-intense, 6/26 hypo-
intense-with-ring, and 1/26 hypointense, but without
enhancing ring. The following histological features asso-
ciated with gadoxetic-acid uptake were identified: num-
ber and type of bile-ducts (pre-existent bile-ducts,
proliferation, and metaplasia), extent of fibrosis, the
presence of inflammation and extent of vascular prolif-
eration.
Conclusion: FNH lesions can be categorized into different
hepatobiliary enhancement patterns on Gadoxetic-acid-
enhanced MRI, which appear to be associated with
histological differences in number and type of bile-ducts,
and varying the presence of fibrous tissue, inflammation,
and vascularization.
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Enhancement characteristics
Focal nodular hyperplasia (FNH) is the second most
frequent benign liver lesion after hemangioma and it is
the most common solid benign liver lesion, comprising
~8 % of all primary hepatic tumors [1–4]. FNH is a well-
circumscribed, usually solitary mass, characterized by a
central fibrous scar with surrounding nodules of hyper-
plastic hepatocytes and small bile ductules. No normal
portal structures are noted, although major vessels may
course through the tumor and are prominent in the fi-
brous scar [2, 5]. FNH is considered to be the result of a
vascular malformation, which leads to hepatocellular
hyperplasia [5, 6]. Considering the bile-ducts within
FNH, Butron et al. [7, 8] have proposed that the ductular
component is not only a proliferation of pre-existing bile-
ducts, but also the result of hepatocellular ductular
metaplasia. FNH’s do not have the potential for malig-
nant transformation and they are not known to cause
bleedings like adenoma [9]. Clinical symptoms due to
mass effect are infrequent. For these reasons, a lesion
diagnosed as FNH in general does not require any
treatment or follow-up.
Owing to the increased use of cross-sectional imaging
techniques, the incidental ﬁnding of a solid liver lesion in
a patient without chronic liver disease or a known pri-
mary tumor is a frequent occurrence in daily radiological
practice. In case of such an incidental ﬁnding, or inci-
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dentaloma, it is important to differentiate between FNH,
which does not require any treatment or follow-up, from
other solid liver lesions like adenoma, hepatocellular
carcinoma, or metastases, as these lesions require either
surveillance or medical or surgical treatment [9].
For the diagnosis of FNH, contrast-enhanced CT,
contrast-enhanced MRI, or contrast-enhanced ultra-
sound (CEUS) is frequently performed. Previous studies
have identiﬁed typical radiological features of FNH’s for
these imaging modalities [10–17]. However, many studies
have reported atypical appearances of FNH on CT, MRI
or CEUS, which may hamper the individual diagnostic
process. The incidence of atypical findings varies widely
between these reports (10–80 %) [18–21]. Consequently,
lesions with atypical findings frequently require further
diagnostic work-up or follow-up, which is time-con-
suming, costly and creates unrest for the patient.
Recently, Gadoxetic acid (Primovist, Bayer Scher-
ing Pharma, Berlin, Germany) has been introduced as a
liver-speciﬁc contrast agent which may facilitate the
differentiation between FNH and non-FNH lesions.
Gadoxetic acid is a hepatobiliary contrast agent which
allows dynamic arterial and portal phase imaging, fol-
lowed by a hepatobiliary phase at 10–20 min. It is
equally cleared by the kidneys and the liver. During the
hepatobiliary phase, progressive contrast uptake is ob-
served in normal functioning liver parenchyma, followed
by enhancement of the bile-duct system, as the contrast is
transported to the biliary canaliculi and subsequently to
the extrahepatic bile-ducts [22]. Zech et al. [17] reported
contrast enhancement during the hepatobiliary phase in
~90 % of FNH’s; as opposed to other focal liver lesions,
such as metastases, hepatocellular carcinoma or ade-
noma, which generally do not show enhancement during
the hepatobiliary phase. However, 5–10 % of HCC le-
sions are reported to demonstrate hepatobiliary contrast
uptake, possible related to OATP-1B1 and/or -1B3 gene-
expression and the presence of bile-duct elements [23].
Zech et al. [17] reported that the majority of FNH
lesions are either homogeneously or inhomogeneously
hyperintense in the hepatobiliary phase, while a minor-
ity demonstrates no enhancement or only peripheral
enhancement. No explanation as to the actual mecha-
nism underlying the different enhancement patterns was
postulated.
This study was designed to meet two goals: 1. to as-
sess the range of hepatobiliary enhancement patterns of
FNH lesions after administration of gadoxetic acid, and
2. to correlate the hepatobiliary enhancement patterns of
FNH lesions to speciﬁc histological features in available
histological specimens obtained after resection or biopsy.
Patients and methods
Identiﬁcation of FNH lesions
This study was Institutional Review Board approved.
Informed consent was waived as no additional investi-
gation was required and the study was performed using
data from routine clinical care.
Between January 2007 and May 2011, 133 consecu-
tive patients underwent Gadoxetic acid-enhanced MRI
of the liver, according to the MR imaging protocol
summarized in Table 1. Of these, 50 patients had colo-
rectal liver metastases, and 21 patients were known to
have chronic liver disease with known or suspected HCC.
Another 62 patients underwent Gadoxetic acid-enhanced
MRI scan of the liver for characterization of a focal liver
lesion, detected as an incidental finding during previous
imaging. In this study, we will focus on this latter group
of patients.
Table 1. MR imaging protocol
Pulse sequence Plane TR TE Flip FOV (mm) Gap (mm) Slice (mm) Matrix
SURVEY insp Axial 2.5 1.27 50 450 3.5 8 192 9 144
SURVEY exp Axial 2.5 1.27 50 450 3.5 8 192 9 144
Refscan Axial 8.0 0.57 56 9 40
T1 TFE bh, insp Axial 8.5 4.2 10 450 0 10 256 9 128
T1 TFE bh, insp Sagittal 8.5 4.2 10 450 0 10 256 9 128
T1 TFE bh, insp Coronal 8.5 4.2 10 450 0 10 256 9 128
T1 TFE bh in + out of phase Axial 181 2.3/4.6 80 375 1 7 224 9 134
T1 FFE RT Axial 10 4.6 15 405 1 7 256 9 126
T1 THRIVE bh (Pre-contrast, 25 and 60 s,
3, 5, and 10 min)a
Axial 3.7 1.76 10 450 -2 4 176 9 124
T2 TSE RT Axial 556 80 90 405 1 7 400 9 215
EPI-DWI b = 0, 50 fb, RT Axial 4095 56 85 360 0 5 128 9 83
EPI-DWI b = 0, 500 fb, RT Axial 4095 56 85 360 0 5 128 9 83
THRIVE bh 20 mina Axial 3.7 1.76 10 450 -2 4 176 9 124
TR repetition time; TE echo time; flip flip angle; FOV field of view; slice slice thickness; TFE turbo field echo; TSE turbo spin echo; FFE fast field
echo; EPI echo planar imaging; SSH single shot; RT respiratory triggered; bh breath hold; fb free breathe; THRIVE T1 weighted high resolution
isotropic volume examination
MRI scans were performed on a 1.5 Tesla MRI scanner (Philips, Best, The Netherlands) using a SenseBody coil
MRI scans were stored in the Picture Archiving and Communication System at the UMC Utrecht (PACS image viewer, Easy Vision Workstation,
Philips Medical Systems, The Netherlands
a After injection of Gd-EOB-DTPA 0.25 lmol/kg bolus at 2 mL/s through an intravenous cubital line, followed by a 25 mL saline chaser
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To identify FNH lesions, all 62 MRI exams were
reviewed during a consensus-reading with a hepatobil-
iary radiologist (MvL 25 years experience), a radiologist
specializing in abdominal radiology (EB 6 years experi-
ence) and a research fellow (CvK). First, non-contrast-
enhanced T1 and T2 weighted sequences, and early dy-
namic sequences (25, and 60 s) were reviewed in order to
assess lesion appearance during the different sequences.
A six-point scale was used to describe lesion intensity as
compared to surrounding liver parenchyma: 1—mark-
edly hypo-intense, 2—moderately hypo-intense, 3—iso-
intense, but visible due to mass effect, 4—moderately
hyperintense, 5—markedly hyperintense, 6—not visible
(iso-intense without mass effect, but visible on at least
one other sequence). If a scar was present, the same six-
point scale was used to describe the signal intensity of the
scar compared to the surrounding lesion. Secondly,
stringent criteria, described in prior studies to be
pathognomonic for FNH, were applied to each detected
liver lesion (Table 2).
FNH lesions included for further study were either
(a) typical FNH lesions on imaging, demonstrating all
typical FNH features described in Table 2, and requir-
ing no further treatment or follow-up as decided by the
weekly convening multidisciplinary tumorboard; or (b)
lesions with one or more atypical findings on imaging,
that were only characterized as FNH after histological
examination of the resected specimen or histological
biopsy.
Enhancement patterns in hepatobiliary phase
Subsequently the hepatobiliary phases (5 and 10 post-
contrast injection) of all FNH lesions were evaluated in
order to identify their hepatobiliary enhancement pat-
terns. Signal intensity in the hepatobiliary phase was
assessed using the above described six-point scale, vary-
ing from markedly hypo-intense to markedly hyper-in-
tense relative to the surrounding liver parenchyma. In
addition, based on prior observations, enhancement
patterns were categorized into one of the following four
patterns: (1) homogeneously hyperintense pattern:
homogeneously hyperintense signal intensity in all parts
of the lesion with possible exception of a central stellate
or linear hypodensity; (2) inhomogeneously hyperintense
pattern: hyperintense signal intensity of the lesion with
scattered 1–5 mm areas of hypo-intense signal intensity
throughout the lesion; (3) iso-intense pattern: lesion is
visible due to mass effect, but with iso-intense signal
intensity, and ﬁnally: (4) ‘‘hypo-intense-with-ring’’ pat-
tern: predominant, non-enhancing, spherical centre sur-
rounded by a thin peripheral rim of hyper-intense signal
intensity.
Histological examination
The available histological specimens of FNH, either
from surgical resection or histological biopsy, were re-
evaluated in order to correlate the histological features
with the observed enhancement patterns. A dedicated
pathologist with hepatobiliary experience (FK 35 years
experience) reviewed all specimens in order to identify
and localize bile-ducts and to characterize bile-ducts
into one of three types, i.e., (1) pre-existent bile-ducts;
(2) bile-duct proliferation (rather well-differentiated
bile-ducts proliferating secondary to increased pres-
sure); or (3) bile-duct metaplasia (dedifferentiation,
or metaplasia of hepatocytes into non-functioning
bile-ducts). Furthermore, the pathologist assessed the
presence of inﬂammation and abnormal vascular con-
ﬁgurations. For the characterization of the bile-ducts
immunohistochemical analysis with CK7 and CK19
was performed (see Table 3). Immunohistochemical
analysis with CD34 was performed to assess the in-
tratumoral vasculature and sinusoidal vessels. In addi-
tion, Azan staining was performed to demonstrate the
extent of fibrous tissue.
Table 2. Overview of typical and atypical FNH features
Typical features Atypical features
Lesion Lesion enhancement is homogeneous during all phases. Marked lesion heterogeneity
T1 Moderately hypo- or iso-intense Strongly hypo- or hyper-intense
T2 Moderately hyper- or iso-intense Strongly hyper- or hypo-intense
Arterial Intense arterial enhancement Minimal or no enhancement
Portal-venous Hyperintense (rapid loss of signal intensity compared to arterial
phase) or iso-intense
Hypo-intense
Equilibrium Iso-intense or moderately hyperintense Hypo-intense or strongly hyper-intense
Scar Obligatory for typical FNH if lesion is >3 cm, and may be
present if lesion is <3 cm
Absence of scar in lesions >3 cm
Presents as a linear or stellate area in the centre of the lesion.
T1 Hypo-intense, relative to the surrounding lesion Hyper-intense
T2 Hyper-intense, relative to the surrounding lesion Hypo-intense
Arterial Non-enhancing
Portal-venous Hypo-intense, relative to the surrounding lesion
Equilibrium Moderately hyperintense or iso-intense Hypo-intense
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Results
Identiﬁcation of FNH lesions
On pre-contrast and early dynamic MRI, a total of 21
typical FNH’s were identiﬁed in 15 patients. Although
presenting with a typical appearance on MRI, histopa-
thology was acquired in one of these lesions. This lesion
occurred in a patient referred with a presumed colorectal
liver metastasis and for that reason surgical resection was
performed. Histopathology was available in another 5
FNH’s in 5 patients (3 surgically treated, 2 histological
biopsies), in whom the MRI appearance and enhance-
ment pattern were not pathognomonic for FNH. This
resulted in a total of 26 FNH’s, varying in size between
0.5 and 11.9 cm (mean 3.1 cm) in 20 patients (15 women,
5 men; mean age 46.1 years, range 28.8–60.9 years). 15
lesions were less than or equal to 3 cm in diameter and 11
lesions were larger than 3 cm in diameter. Four patients
presented with more than one FNH (range 1–4), the
other 16 patients presented with a solitary lesion. For
further details see Fig. 1.
FNH appearance on hepatobiliary images
Ten lesions (10/26, 38 %) demonstrated a homoge-
neously hyperintense pattern (mean size 2.3 cm, range
Fig. 1. Flowchart of FNH identification
Table 3. Overview of CK7, CK19 and CD34 characteristics
Glycoprotein Function
CK 7 Cytokeratin 7 is a protein belonging to the type I Keratin family, and is used to identify bile-ducts. The keratins are intermediate
filament proteins responsible for the structural integrity of epithelial cells. CK 7 in hepatocytes is upregulated by cholestasis
and therefore an upregulation of CK 7 is seen in areas with dedifferentiation of normal hepatocytes to bile-ducts (ductular
metaplasia) and areas with bile-duct proliferation
CK 19 Cytokeratin 19 is also a protein belonging to the type I Keratin family, and is also called a bile-duct type keratin. In the liver
CK 19 is expressed by well-differentiated (native) bile-ducts and can therefore be present in focal nodular hyperplasia.
CK 19 expression can therefore be observed in areas with pre-existent bile-ducts and ductular proliferation
CD34 CD 34 is a cell surface glycoprotein that functions as cell–cell adhesion factor. CD 34 is expressed by (premature) hematopoietic
and vascular associated tissue. CD 34 expression by sinusoid endothelial cells is associated to the process of angiogenesis.
Diffuse expression of CD 34 is a sign of carcinogenesis and is seen in hepatocellular carcinoma. Non-diffuse expression
of CD34 can be seen in FNH in areas with sinusoidal proliferation
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0.5–6.4 cm; 3 lesions >3 cm, 7 lesions <3 cm) (Fig. 2a–
f). A thin, stellar or linear hypodensity, interpreted as the
central scar on early dynamic sequences, was visible
during the hepatobiliary phases in all 3 lesions larger
than 3 cm and in none of the lesions smaller than 3 cm.
Four lesions (4/26, 15 %) showed an inhomogeneously
hyperintense pattern (Fig. 3a–f), where 1–5 mm nodular
areas of hypo-intense signal were scattered throughout
the enhancing lesion without the presence of a typical
scar (mean size 5.9, range 2.5–11.9 cm, one lesion
<3 cm, 3 lesions >3 cm). Six lesions (6/26, 23 %)
demonstrated a ‘‘hypointense-with-ring’’ pattern (mean
size 1.9 cm, range 1.0–2.6 cm, all lesions <3 cm)
(Fig. 4a–f). Five lesions (5/26, 19 %) showed an
iso-intense pattern with mass effect (mean size 3.5 cm,
range 1.7–5.3 cm; 2 lesions <3 cm, 3 lesions >3 cm)
(Fig. 5a–f), with a scar present in all three lesions larger
than 3 cm.
One lesion could not be categorized into one of these
four patterns. This lesion (5.5 cm) appeared hyperintense
during early dynamic phases, but signal intensity de-
creased during hepatobiliary phases, resulting in a
slightly hypo-intense signal compared to the surrounding
parenchyma. This lesion was homogeneously hypo-in-
tense, and did not show a peripheral rim like the ‘‘hypo-
intense-with-ring’’ type FNH’s (Fig. 6a–f).
Correlation between histopathological features
and appearance on hepatobiliary phase
Histopathology was available in six lesions (further ref-
erenced as Tumors A–F); four resection specimens
Fig. 2. A patient
presenting with a typical






A–F The FNH is visible on
T1, T2, and during arterial
phase, portal-venous
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(Tumors A–D) and two core-biopsies (Tumors E and F)
(see Table 4).
In each of these lesions an inﬂammatory component
with lymphocyte inﬁltration was observed, although the
degree of inﬂammation differed. Second, an increase in
bile-ducts compared to the surrounding, normal paren-
chyma was observed in all six lesions. Using immuno-
histochemistry, three different types of bile-ducts were
observed, i.e.: CK19 positive pre-existent (normal) bile-
ducts, CK7 positive ductular proliferation with or with-






(Tumor C). A–F The FNH is
visible on T1, T2, and during
arterial phase, portal-
venous phase, and 5 and
10 min hepatobiliary phase,
respectively (white and
black arrows). Initially, the
lesion presents as a
hyperintense lesion with a
non-enhancing central scar
during arterial phase, but










(brown staining at arrows).
H Hematoxylin and eosin
staining showing an
abnormal, enlarged vessel




phase is presumably related
to areas with ischemic injury
and ductular metaplasia due
to vascular abnormalities,
which are alternated by
areas with ductular
proliferation.
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out CK19 positivity, and CK7 positive but CK19 nega-
tive ductular metaplasia. The relative proportion of
pre-existent bile-ducts, ductular proliferation, and duc-
tular metaplasia differed widely between the six lesions.
In addition, the localization (lesion centre, lesion
periphery, or both) of the three bile-duct types differed
between different lesions.
One FNH lesion showed a ‘‘hypointense-with-ring’’
pattern during the hepatobiliary phases (Tumor A). This
lesion was slightly positive for CK19, only in the
periphery of the lesion, correlating with pre-existent
bile-ducts as well as some ductular proliferation (both
well-differentiated bile-ducts). The presence of these well-
differentiated bile-ducts in the lesion periphery appar-
ently resulted in contrast uptake and excretion given the
ring pattern on hepatobiliary phase. Conversely, the core
of this lesion consisted of abundant ﬁbrous tissue sur-
rounded by inﬂammation and CK7 positive bile-duct
metaplasia, resulting in a hypointense appearance of the
lesion centre. Also, some CK7 positive bile-duct prolif-
eration was observed mainly toward the periphery of the
lesion, and only sparsely in the lesion centre (Fig. 4).
Interestingly, despite the presence of some bile-duct
proliferation surrounding the fibrous tissue, contrast
uptake was absent in that area (given the hypo-intense
aspect of the lesions centre on hepatobiliary phase),
suggesting that these bile-ducts were not functional.
Seemingly, in this lesion the capacity of contrast uptake
and excretion was impaired in areas lacking pre-existent
bile-ducts but with bile-duct metaplasia, CK7 positive
bile-duct proliferation, inflammation and fibrosis. In
addition, an upregulation of the angiogenesis marker
CD34 was observed in the core of these ring-enhancing
lesions, indicating vascular proliferation. To our knowl-
edge, the effect of vascular proliferation on Gadoxetic
acid uptake has not yet been established.
Another resected FNH (Tumor B) also presented
with a hypointense hepatobiliary pattern, but without an
enhancing ring (Fig. 6). Histologically, this lesion was
characterized by foci of fibrosis throughout the lesion,
but without a central scar. There were no pre-existent
bile-ducts in this lesion. CK7 staining was diffusely po-
sitive mainly as a result of extensive ductular metaplasia,
and in the periphery of the lesion due to ductular pro-
liferation. This ductular proliferation was only partially
and weakly CK19 positive. In addition, an upregulation
of CD34 was observed throughout the lesion, indicating
vascular proliferation. Interestingly, despite the presence
of ductular proliferation (which are generally well-dif-
ferentiated bile-ducts); this lesion showed impaired con-
Fig. 4. Patient with a histologically proven FNH (Tumor A)
presenting as a hyperintense lesion during early dynamic
phases and presenting as a hypo-intense-with-ring type FNH
during hepatobiliary phases. A–F The FNH is visible on T1, T2,
and during arterial phase, portal-venous phase, and 5 and
10 min hepatobiliary phase, respectively (white and black ar-
rows). The FNH is visible during all phases and initially presents
as a hypervascular lesion on arterial phase with a central scar.
In hepatobiliary phase, a larger hypo-intense core develops,
whilst the periphery of the lesion is persistently hyperintense.
G Azan staining on a whole mount section of the lesion with the
presence of abundant fibrous tissue in the center (arrow).
H CK7 immunohistochemistry on the resection specimen (whole
mount). Brown colored areas represent ductular proliferation
and ductular metaplasia. J an enlargement of the periphery of
the lesion showing pre-existent bile-ducts, ductular metaplasia
and some ductular proliferation, while K is an enlargement of the
lesion centre surrounding the fibrous tissue, showing a combi-
nation of ductular proliferation and ductular metaplasia, al-
though the ductular metaplasia is more pronounced.
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trast uptake compared to the surrounding liver paren-
chyma, suggesting that these proliferative ducts were not
fully functional. Similar to Tumor A, this lesion there-
fore shows that the capacity of contrast uptake and
excretion is impaired in areas with bile-duct metaplasia
and inflammation, as well as in areas with CK7 positive
ductular proliferation but no pre-existent bile-ducts.
Two other resected FNH lesions showed an inho-
mogeneous hepatobiliary enhancement pattern (Tumors
C and D). These lesions were histologically characterized
by multiple necrotic areas, judged to be induced by
vascular malformations (CD34 positivity), and areas
with cirrhotic transformation due to bile congestion
(Fig. 3). Furthermore, diffuse foci of fibrous septae were
observed in both lesions. In Tumor C, the areas of
necrosis and cirrhosis were surrounded by well-differen-
tiated pre-existent bile-ducts and ductular proliferation
(CK19 positive areas). CK7 staining was strongly posi-
tive for ductular metaplasia, not for ductular prolifera-
tion. In Tumor D, CK19 staining was only marginally
positive for some pre-existent bile-ducts; no CK19 posi-
tive ductular proliferation was observed. On the other
hand, this lesion was strongly positive for CK7 positive
ductular proliferation throughout the lesion, without any
signs of metaplasia. Thus, in contrast to Tumor A and B,
these tumors had a more heterogeneous histological
appearance. Furthermore, Tumor A and B showed a
single predominant hypo-intense core with (A) or with-
out (B) a thin rim of peripheral enhancement, while
Tumor C and D showed multiple areas of hypo-intensity
due to diminished contrast uptake and excretion alter-
nated with multiple areas of hyperintensity consistent
Fig. 5. A patient
presenting with a typical





A–F The FNH is visible on
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with the presence of well-differentiated (pre-existent)
bile-ducts.
In Tumor E and F histology of 18G biopsies was
available, therefore limiting the possibility to give details
about the proportion or localization of the observed
histological features. In Tumor E a similar inhomoge-
neously hyperintense pattern was observed on hepatob-
iliary phase as in Tumor C and D. CK7 and CK19
staining were not performed due to limited available
tissue. However, hematoxylin and eosin (HE) staining
did show strong bile-duct proliferation, which might
explain the hyperintense appearance of the lesion. Fur-
thermore, extensive ﬁbrosis and cirrhosis was observed
together with a strong lymphocytic inﬁltration. These
areas probably correlate to the areas of diminished
contrast uptake. Tumor F showed an iso-intense pattern
during the hepatobiliary phases, indicating a similar
amount of contrast uptake as the surrounding paren-
chyma. Histology of Tumor F revealed clear CK19 po-
sitive bile-ducts consistent with ductular proliferation
and pre-existent bile-ducts. Furthermore, CK7 staining
was positive as a result of ductular metaplasia. Finally,
hyperplasia of the vessel intima was observed as well as
ﬁbrotic areas probably induced by necrosis of the hepa-
tocytes. Contrast uptake is likely to be diminished in
these areas. Despite the presence of pre-existent bile-
ducts, this lesion showed an iso-intense pattern (similar
uptake as surrounding (parenchyma) instead of a
hyperintense pattern. Presumably because pre-existent
bile-ducts were surrounded by areas of ductular meta-
plasia and ﬁbrosis.
Discussion
This study shows that hepatobiliary enhancement patterns
of FNH’s may present as one of four patterns: homoge-
neous hyperintense, inhomogeneous hyperintense, iso-in-
tense, and hypo-intense with or without peripheral
enhancement.Histological evaluation revealed differences
in number, type, and localization of bile-ducts between
individual FNH lesions as well as differences in inﬂam-
matory component, extent of ﬁbrous tissue and the pres-
ence of vascular proliferation. Comparison of histology
with imaging features suggests that the observed
enhancement patterns can largely be explained by differ-
ences in histological features of these lesions.
Fig. 6. Another patient presenting with a hypo-intense type
FNH in segment 5 (Tumor B). A–F The FNH is visible on T1,
T2, and during arterial phase, portal-venous phase, and 5 and
10 min hepatobiliary phase, respectively (white and black
arrows). The FNH is visible during all phases and initially
presents as a hypervascular lesion on arterial phase without a
central scar. During hepatobiliary phases, the lesion signal is
less intense compared to the surrounding parenchyma,
resulting in a slightly hypointense aspect. G CK 19 immuno-
histochemistry showing weakly CK 19 positive ductular pro-
liferation in the lesion periphery (arrows), while the lesion
centre is almost completely negative. H CK7 immunohisto-
chemistry shows diffuse positivity in the lesion representing
both ductular proliferation and ductular metaplasia (black ar-
rows); the bile-ducts that are positive for CK19 (G) are posi-
tive for CK7 as well (red arrows). The ductular metaplasia is
more pronounced than the ductular proliferation and is visible
both in the lesion centre as in the lesion periphery. J CD34
immunohistochemistry shows expression around the fibrous
tissue (arrows). K Azan staining demonstrates the presence
of fibrous tissue throughout the lesion (black arrows pointing
out blue areas), although a central scar cannot be identified.
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Previously, Zech et al. [17] described three hepatob-
iliary enhancement patterns in FNH (homogeneously
hyperintense, inhomogeously hyperintense, and periph-
eral enhancement), all with a hyperintense nature. In
addition, Zech et al. reported that no enhancement oc-
curred during the hepatobiliary phase in 10–12 % of
FNH’s. In our study, we observed similar enhancement
patterns, although only one out of 26 included lesions
was homogeneously hypo-intense during the hepatobil-
iary phase. Possibly in the study of Zech, lesions with a
hypointense-with-ring pattern were described as non-
enhancing lesions, interpreting the thin peripheral
enhancing rim as part of the surrounding liver paren-
chyma, resulting in a higher percentage of ‘‘non-
enhancing’’ FNH.
In this study, we analyzed the histological features of
FNH’s in order to better understand the mechanisms of
Gadoxetic acid uptake and excretion in relation to the
observed enhancement patterns. A better understanding
of enhancement patterns and mechanisms might be
beneﬁciary for lesion characterization, which is impor-
tant as the prevalence of FNH is high. In this study,
FNH was diagnosed in the majority (34/62; i.e., 55 %) of
patients who were referred for characterization of an
incidental ﬁnding in the liver.
Previously it has been shown that FNH’s can have
various degrees of inﬂammation, which is induced by
either a response to ischemic injury secondary to vascular
malformation or by cholangitis secondary to bile
obstruction [24]. Our data support these results as
inflammation was detected in all six histologically eval-
uated lesions, although the degree of inflammation dif-
fered strongly between the lesions.
So far, it is accepted that Gadoxetic acid uptake is
only possible in functioning hepatocytes and that func-
tioning bile-ducts are necessary for excretion in the bile-
system. Therefore, in our histological evaluation special
emphasis was put on evaluation of bile-ducts.
Owing to increased intraparenchymal pressure, duc-
tular metaplasia of hepatocytes and proliferation of
bile-ducts can be induced [7, 8, 25]. These proliferative
bile-ducts can be well-differentiated with preserved
function, and therefore, Gadoxetic uptake and accumu-
lation can be expected. In FNH, the increased pressure
might be secondary to vascular malformation resulting in
increased blood-flow to a specific region compared to the
surrounding tissue, or as a result of ischemia [6]. In our
study, we observed an increase in well-differentiated bile-
ducts (either pre-existent bile-ducts, or well-differentiated
proliferative bile-ducts) compared to the surrounding
parenchyma in all lesions, although the number of well-
differentiated bile-ducts differed between lesions. The
increased number of well-differentiated bile-ducts, espe-
cially of pre-existent bile-ducts, seemed to correlate with
increased contrast accumulation, thereby explaining the
hyperintense appearance of FNH’s.
Apart from areas with well-differentiated bile-ducts,
areas of hepatocytic bile-duct metaplasia were observed.
Bile-duct metaplasia can evolve into proliferation of bile-
ducts with diminished functionality and inadequate
linkage to the bile canaliculi. Bile-duct metaplasia is
initiated by chronic inﬂammation, cholangitis, or bile
ﬂow obstruction and all of these components can to a
lesser or greater extent be present in FNH [25]. We ob-
served less contrast uptake in the areas with ductular
metaplasia and in some areas with ductular proliferation,
which might be explained by the diminished functionality
of these bile canaliculi, resulting in locally diminished
excretion of Gadoxetic acid.
We also observed differences in the distribution of the
different bile-duct types throughout the lesions (lesion
centre vs. lesion periphery) and this distribution differed
between the hypo-intense-with-ring FNH’s, the hypo-
intense FNH’s and the inhomogeneously hyperintense
FNH’s. In the ring-type FNH we observed ﬁbrous tissue
in the lesion centre surrounded by some inﬂammation
and vascular proliferation with ductular metaplasia,
while the lesion periphery consisted mainly of well-dif-
ferentiated pre-existent bile-ducts without signs of
metaplasia, ﬁbrous tissue, or inﬂammation. Although the
hypo-intense FNH (lesion B) demonstrated pronounced
ductular proliferation in the lesion periphery, no ring-
phenomenon was observed in the hepatobiliary phase.
This was probably because the periphery also consisted
of ductular metaplasia, and pre-existent bile-ducts were
lacking. In both inhomogeneously hyperintense FNH’s
with resected specimens available, we observed more
inﬂammation and lymphocyte inﬁltration, with multiple
areas of ﬁbrous tissue throughout the lesions that were
accompanied by areas of vascular malformation. Inter-
estingly, bile-duct metaplasia was only observed in one of
these lesions (Tumor C). Both lesions also contained
large areas with ductular proliferation (CK19 positive in
Tumor C, CK7 positive in tumor D) containing well-
differentiated bile-ducts, while pre-existent bile-ducts
were predominantly observed in Tumor C. These well-
differentiated bile-ducts might explain the hyperintense
appearance of these lesions on hepatobiliary phase. Bile-
duct localization could not be assessed accurately in both
lesions with histology obtained by means of 18G core-
biopsy.
There are several limitations to our study. Histology
was only available in six lesions, whilst the standard of
reference for the other 20 FNH lesions consisted of
typical ﬁndings on pre-contrast and early dynamic
sequences. However, the stringent criteria used to non-
invasively identify these FNH lesions are generally
accepted as pathognomonic for FNH, obviating the need
for further imaging or follow-up. We did not perform
quantiﬁcation of the various components of the hepa-
tobiliary phase enhancement patterns, reasoning that
visual assessment is the cornerstone for pattern recog-
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nition and quantiﬁcation of the observed phenomena
would not serve a practical purpose. The inclusion of
only FNH lesions that were either proven on pathology
or those demonstrating the complete set of pathogno-
monic MR imaging features on pre-contrast and early
dynamic phases, leaves the possibility that other FNH
lesions, with one or more atypical features on pre-con-
trast or early dynamic MR imaging, might show different
hepatobiliary enhancement patterns. Therefore, we per-
formed a post hoc analysis on the 14 patients who had
received a clinical diagnosis of having at least one FNH
lesion but who, according to the study protocol, were
excluded from further analysis because of one or more
atypical MR imaging features of the observed FNH le-
sions. A total of 20 lesions clinically characterized as
FNH were detected in these 14 patients. All 20 lesions
could be categorized into one of the four described
hepatobiliary enhancement patterns (homogeneously
hyperintense n = 11, inhomogeneously hyperintense
n = 3, iso-intense n = 5, ring-type n = 1) and no
additional enhancement patterns were seen. All 14 pa-
tients received a minimum of 1 year follow-up with MRI,
demonstrating no growth or change of the observed
morphological features, consistent with the clinical
diagnosis of FNH. Finally, the design of the study leaves
the possibility that lesions with other pathology than
FNH might also show one of the observed hepatobiliary
enhancement patterns. Although we cannot rule out this
possibility, we have not observed the described hepa-
tobiliary enhancement patterns in other pathology than
FNH.
In conclusion, FNH lesions can be categorized into
one of four hepatobiliary enhancement patterns on
Gadoxetic-acid-enhanced MRI. These various enhance-
ment patterns appear to be associated with histological
differences in number and type of bile-ducts, and with
varying the presence and distribution of ﬁbrous tissue,
inﬂammation, and vascularization.
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